Fri, Nov 28, 2014, 7:28 AM EST - U.S. Markets open in 2 hrs 2 mins


% | $
Quotes you view appear here for quick access.

Repros Therapeutics Inc. (RPRX) Message Board

  • dmp2122003 dmp2122003 Jan 30, 2013 9:43 AM Flag

    Repros Therapeutics weakness creates buying opportunity, says Roth Capital

    After Repros' stock sold off yesterday, Roth Capital spoke with the company's management and is more confident that the outlook for the company's Androxal drug remains positive. The firm maintains a $19 price target and Buy rating on the stock.

    Sentiment: Strong Buy

9.02+0.27(+3.09%)Nov 26 4:00 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.